



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

May 11, 2021: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**
  
- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**  
(Public Comment Prior to Board Action)
  
- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**
  
- **Medical Director Update** **6:45 - 6:50**
  
- **Follow-up Items from Previous Meetings** **6:50 – 7:00**
  - Chantix (Varenicline) Use
  
- **RetroDUR/ProDUR** **7:00- 7:25**
  - Introduce: Long-Acting Injectable Antipsychotics
  - Data presentation: Codeine Use in the Pediatric Population
  
- **Clinical Update: Drug Reviews** **7:25-7:55**  
(Public comment prior to Board action)
  
- **Biosimilar Drug Reviews**
  - None at this time
  
- **Full New Drug Reviews**  
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
  - Cystadrops® (cysteamine- ophthalmic solution)
  - Lampit® (nifurtimox tablets)
  - Oxlumio® (lumasiren)
  - Reditrex® (methotrexate)
  - Sevenfact® (coagulation factor VIIa [recombinant]-jncw)
  - Sutab® (sodium sulfate, magnesium sulfate, and potassium chloride)
  
- **New Managed Therapeutic Drug Classes** **7:55 -7:55**  
(Public comment prior to Board action)
  - None at this time
  
- **Therapeutic Drug Classes – Periodic Review** **7:55 - 8:20**  
(Public comment prior to Board action)
  - Analgesics, Narcotics- Long Acting

- Analgesics, Narcotics- Short Acting
- Epinephrine, Self-Injectable
- Hepatitis B
- Multiple Sclerosis Agents (new drug Kesimpta® (ofatumumab) included)
- Neuropathic Pain/Fibromyalgia Agents
- Pseudobulbar Affect Agents
- Topical Steroids
  
- **Review of Newly Developed/Revised Criteria** **8:20 - 8:30**  
(Public comment prior to Board action)
  - Acne Agents: Topical Retinoids
  - Hyperkalemia Agents
  
- **General Announcements** **8:30 – 8:30**
  
- **Adjourn** **8:30**